Erik Ostrowski sold $62k of AKBA
SVP, CFO, CBO & Treasurer at Akebia Therapeutics, Inc.. 56,019 shares at an average of $1.11, traded Jun 29, 2026, filed Jul 1, 2026.
Score components
- +22RoleCFO
- +7Trade size$62k at market
- 0Share of holdings soldSold 8.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001762507-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -56,019 | $1.11 | $62k | 616,616 | Jul 1, 2026 |
Related signals
Other insiders at Akebia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | AKBAbuy Akebia Therapeutics, Inc. | John P. Butler CEO and President | $87k 69,270 shares | +2% | |
| 37Weak | Akebia Therapeutics, Inc. | John P. Butler CEO and President | $474k 341,305 shares | -10% | |
| 20Weak | Akebia Therapeutics, Inc. | Steven Keith Burke SVP, Chief Medical Officer | $94k 67,658 shares | -7% | |
| 25Weak | Akebia Therapeutics, Inc. | Nicholas Grund Chief Commercial Officer | $118k 84,829 shares | -13% | |
| 24Weak | Akebia Therapeutics, Inc. | Erik Ostrowski SVP, CFO, CBO & Treasurer | $49k 34,951 shares | -5% | |
| 23Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $69k 49,524 shares | -14% | |
| 25Weak | Akebia Therapeutics, Inc. | Carolyn M. Rucci SVP, Chief Legal Officer | $97k 69,772 shares | -11% | |
| 13Weak | Akebia Therapeutics, Inc. | Erik Ostrowski SVP, CFO, CBO & Treasurer | $152k 41,314 shares | -8% | |
| 0Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $60k 15,000 shares | -5% | |
| 1Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $47k 13,334 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.